Potential of Low Dose Leuco-Methylthioninium Bis(Hydromethanesulphonate) (LMTM) Monotherapy for Treatment of Mild Alzheimer's Disease: Cohort Analysis as Modified Primary Outcome in a Phase III Clinical Trial
ContributorsWilcock, Gordon K; Gauthier, Serge; Frisoni, Giovanni; Jia, Jianping; Hardlund, Jiri H; Moebius, Hans J; Bentham, Peter; Kook, Karin A; Schelter, Bjoern O; Wischik, Damon J; Davis, Charles S; Staff, Roger T; Vuksanovic, Vesna; Ahearn, Trevor; Bracoud, Luc; Shamsi, Kohkan; Marek, Ken; Seibyl, John; Riedel, Gernot; Storey, John M D; Harrington, Charles R; Wischik, Claude M
Published inJournal of Alzheimer's Disease, vol. 61, no. 1, p. 435-457
Publication date2018
Abstract
Keywords
- Aged
- Aged, 80 and over
- Alzheimer Disease/diagnostic imaging/drug therapy
- Antipsychotic Agents/therapeutic use
- Cohort Studies
- Double-Blind Method
- Female
- Humans
- International Cooperation
- Male
- Mental Status and Dementia Tests
- Methylene Blue/analogs & derivatives/therapeutic use
- Middle Aged
- Treatment Outcome
Affiliation entities
Research groups
Citation (ISO format)
WILCOCK, Gordon K et al. Potential of Low Dose Leuco-Methylthioninium Bis(Hydromethanesulphonate) (LMTM) Monotherapy for Treatment of Mild Alzheimer’s Disease: Cohort Analysis as Modified Primary Outcome in a Phase III Clinical Trial. In: Journal of Alzheimer’s Disease, 2018, vol. 61, n° 1, p. 435–457. doi: 10.3233/JAD-170560
Main files (1)
Article (Published version)
Identifiers
- PID : unige:116075
- DOI : 10.3233/JAD-170560
- PMID : 29154277
Journal ISSN1387-2877
